{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:57:12Z","timestamp":1780484232712,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172052"],"award-info":[{"award-number":["82172052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["Z210007"],"award-info":[{"award-number":["Z210007"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022CR34"],"award-info":[{"award-number":["2022CR34"]}]},{"name":"Youth Clinical Research Special Fund Project of Peking University First Hospital","award":["2023YC26"],"award-info":[{"award-number":["2023YC26"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00259-025-07306-y","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:50:36Z","timestamp":1746474636000},"page":"4511-4524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET\/CT"],"prefix":"10.1007","volume":"52","author":[{"given":"Yuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5740-0602","authenticated-orcid":false,"given":"Jingming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-3014","authenticated-orcid":false,"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-3163","authenticated-orcid":false,"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"7306_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced Triple-Negative breast Cancer. N Engl J Med. 2022;387:217\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2202809.","journal-title":"N Engl J Med"},{"key":"7306_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30:249\u201356. https:\/\/doi.org\/10.1038\/s41591-023-02677-x.","journal-title":"Nat Med"},{"key":"7306_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early Triple-Negative breast Cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"7306_CR4","doi-asserted-by":"publisher","unstructured":"Cardoso F, O\u2019Shaughnessy J, McArthur H, Schmid P, Cort\u00e9s J, Harbeck N, et al. Abstract GS01-02: phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+\/HER2\u2013\u2009breast cancer: KEYNOTE-756. Cancer Res. 2024;84. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-gs01-02. GS01-2-GS-2.","DOI":"10.1158\/1538-7445.Sabcs23-gs01-02"},{"key":"7306_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s0140-6736(20)31953-x","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant Atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u2013100. https:\/\/doi.org\/10.1016\/s0140-6736(20)31953-x.","journal-title":"Lancet"},{"key":"7306_CR6","doi-asserted-by":"publisher","first-page":"e2342107","DOI":"10.1001\/jamanetworkopen.2023.42107","volume":"6","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early Triple-Negative breast cancer: A secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2342107. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.42107.","journal-title":"JAMA Netw Open"},{"key":"7306_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2022;31:549\u201355. https:\/\/doi.org\/10.1080\/13543784.2022.2008354.","journal-title":"Expert Opin Investig Drugs"},{"key":"7306_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/jco.20.02923","volume":"39","author":"AS Alva","year":"2021","unstructured":"Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, et al. Pembrolizumab in patients with metastatic breast Cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 2021;39:2443\u201351. https:\/\/doi.org\/10.1200\/jco.20.02923.","journal-title":"J Clin Oncol"},{"key":"7306_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21:529\u201340. https:\/\/doi.org\/10.1038\/s41573-022-00493-5.","journal-title":"Nat Rev Drug Discov"},{"key":"7306_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, et al. Classification of tumor immune microenvironment according to programmed Death-Ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC. J Thorac Oncol. 2023;18:869\u201381. https:\/\/doi.org\/10.1016\/j.jtho.2023.03.012.","journal-title":"J Thorac Oncol"},{"key":"7306_CR11","doi-asserted-by":"publisher","first-page":"102257","DOI":"10.1016\/j.ctrv.2021.102257","volume":"99","author":"C Boman","year":"2021","unstructured":"Boman C, Zerdes I, M\u00e5rtensson K, Bergh J, Foukakis T, Valachis A, et al. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2021;99:102257. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102257.","journal-title":"Cancer Treat Rev"},{"key":"7306_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/s1470-2045(20)30592-1","volume":"21","author":"R Salgado","year":"2020","unstructured":"Salgado R, Bellizzi AM, Rimm D, Bartlett JMS, Nielsen T, Holger M, et al. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol. 2020;21:1399\u2013401. https:\/\/doi.org\/10.1016\/s1470-2045(20)30592-1.","journal-title":"Lancet Oncol"},{"key":"7306_CR13","doi-asserted-by":"publisher","unstructured":"Lo Gullo R, Wen H, Reiner JS, Hoda R, Sevilimedu V, Martinez DF, et al. Assessing PD-L1 expression status using radiomic features from Contrast-Enhanced breast MRI in breast Cancer patients: initial results. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13246273.","DOI":"10.3390\/cancers13246273"},{"issue":"Suppl 1","key":"7306_CR14","doi-asserted-by":"publisher","first-page":"s17","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. \u00b9\u2078F-FDG PET\/CT for staging and restaging of breast Cancer. J Nucl Med. 2016;57(Suppl 1):s17\u201326. https:\/\/doi.org\/10.2967\/jnumed.115.157859.","journal-title":"J Nucl Med"},{"key":"7306_CR15","doi-asserted-by":"publisher","first-page":"188861","DOI":"10.1016\/j.bbcan.2023.188861","volume":"1878","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang H, Luo Y, Tuo B, Liu X, Li T. Effect of metabolism on the immune microenvironment of breast cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188861. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188861.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7306_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-020-05619-0","volume":"181","author":"T Hirakata","year":"2020","unstructured":"Hirakata T, Fujii T, Kurozumi S, Katayama A, Honda C, Yanai K, et al. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Res Treat. 2020;181:331\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05619-0.","journal-title":"Breast Cancer Res Treat"},{"key":"7306_CR17","doi-asserted-by":"publisher","first-page":"108773","DOI":"10.1016\/j.ejrad.2019.108773","volume":"123","author":"W Murakami","year":"2020","unstructured":"Murakami W, Tozaki M, Sasaki M, Hida AI, Ohi Y, Kubota K, et al. Correlation between (18)F-FDG uptake on PET\/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol. 2020;123:108773. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108773.","journal-title":"Eur J Radiol"},{"key":"7306_CR18","doi-asserted-by":"publisher","first-page":"110661","DOI":"10.1016\/j.ejrad.2022.110661","volume":"158","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Higuchi T, Fujimoto Y, Ishikawa E, Yokoyama H, Komoto H, et al. Relationship between FDG-PET and the immune microenvironment in breast cancer. Eur J Radiol. 2023;158:110661. https:\/\/doi.org\/10.1016\/j.ejrad.2022.110661.","journal-title":"Eur J Radiol"},{"key":"7306_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC Cancer staging manual: breast Cancer. Ann Surg Oncol. 2018;25:1783\u20135. https:\/\/doi.org\/10.1245\/s10434-018-6486-6.","journal-title":"Ann Surg Oncol"},{"key":"7306_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403\u201310. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology"},{"key":"7306_CR21","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/jco.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of Estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784\u201395. https:\/\/doi.org\/10.1200\/jco.2009.25.6529.","journal-title":"J Clin Oncol"},{"key":"7306_CR22","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/jco.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"7306_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s44178-022-00007-8","volume":"1","author":"J Wu","year":"2022","unstructured":"Wu J, Fan D, Shao Z, Xu B, Ren G, Jiang Z, et al. CACA guidelines for holistic integrative management of breast Cancer. Holist Integr Oncol. 2022;1:7. https:\/\/doi.org\/10.1007\/s44178-022-00007-8.","journal-title":"Holist Integr Oncol"},{"key":"7306_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdu450.","journal-title":"Ann Oncol"},{"key":"7306_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40644-024-00812-6","volume":"24","author":"Y Gao","year":"2024","unstructured":"Gao Y, Yin L, Ma L, Wu C, Zhu X, Liu H, et al. Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET\/CT imaging. Cancer Imaging. 2024;24:166. https:\/\/doi.org\/10.1186\/s40644-024-00812-6.","journal-title":"Cancer Imaging"},{"key":"7306_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with pembrolizumab in early Triple-Negative breast Cancer. N Engl J Med. 2022;386:556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"key":"7306_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33:1149\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940.","journal-title":"Ann Oncol"},{"key":"7306_CR28","doi-asserted-by":"publisher","unstructured":"Huang K, Hu M, Chen J, Wei J, Qin J, Lin S, et al. Multi-Omics perspective reveals the different patterns of tumor immune microenvironment based on programmed death ligand 1 (PD-L1) expression and predictor of responses to immune checkpoint Blockade across Pan-Cancer. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22105158.","DOI":"10.3390\/ijms22105158"},{"key":"7306_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cmet.2023.06.003","volume":"35","author":"W Zou","year":"2023","unstructured":"Zou W, Green DR. Beggars banquet: metabolism in the tumor immune microenvironment and cancer therapy. Cell Metab. 2023;35:1101\u201313. https:\/\/doi.org\/10.1016\/j.cmet.2023.06.003.","journal-title":"Cell Metab"},{"key":"7306_CR30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","volume":"48","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X, et al. 2-[18F]FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:570\u20139. https:\/\/doi.org\/10.1007\/s00259-020-04996-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7306_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnmt.111.090027","volume":"39","author":"E Laffon","year":"2011","unstructured":"Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver SUV stable over time in \u00b9\u2078F-FDG PET imaging? J Nucl Med Technol. 2011;39:258\u201363. https:\/\/doi.org\/10.2967\/jnmt.111.090027.","journal-title":"J Nucl Med Technol"},{"key":"7306_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/ajr.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310\u201320. https:\/\/doi.org\/10.2214\/ajr.10.4923.","journal-title":"AJR Am J Roentgenol"},{"key":"7306_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B, O\u2019Malley MMR, Kay J, Mueller SN, et al. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24:554\u201377. https:\/\/doi.org\/10.1038\/s41568-024-00714-6.","journal-title":"Nat Rev Cancer"},{"key":"7306_CR34","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1007\/s00259-021-05399-9","volume":"48","author":"C Wu","year":"2021","unstructured":"Wu C, Cui Y, Liu J, Ma L, Xiong Y, Gong Y, et al. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[(18)F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:4054\u201366. https:\/\/doi.org\/10.1007\/s00259-021-05399-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7306_CR35","doi-asserted-by":"publisher","unstructured":"Zhou J, Zou S, Kuang D, Yan J, Zhao J, Zhu XA, Novel Approach. Using FDG-PET\/CT-Based radiomics to assess tumor immune phenotypes in patients with Non-Small cell lung Cancer. Front Oncol. 2021;11:769272. https:\/\/doi.org\/10.3389\/fonc.2021.769272.","DOI":"10.3389\/fonc.2021.769272"},{"key":"7306_CR36","doi-asserted-by":"publisher","first-page":"559623","DOI":"10.3389\/fonc.2021.559623","volume":"11","author":"J Zhou","year":"2021","unstructured":"Zhou J, Zou S, Cheng S, Kuang D, Li D, Chen L, et al. Correlation between Dual-Time-Point FDG PET and tumor microenvironment immune types in Non-Small cell lung Cancer. Front Oncol. 2021;11:559623. https:\/\/doi.org\/10.3389\/fonc.2021.559623.","journal-title":"Front Oncol"},{"key":"7306_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13058-023-01606-7","volume":"25","author":"T Hanamura","year":"2023","unstructured":"Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, et al. Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. Breast Cancer Res. 2023;25:13. https:\/\/doi.org\/10.1186\/s13058-023-01606-7.","journal-title":"Breast Cancer Res"},{"key":"7306_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.03.011","volume":"46","author":"MV Dieci","year":"2016","unstructured":"Dieci MV, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: is it really a dead end? Cancer Treat Rev. 2016;46:9\u201319. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.011.","journal-title":"Cancer Treat Rev"},{"key":"7306_CR39","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00259-023-06150-2","volume":"50","author":"K Chen","year":"2023","unstructured":"Chen K, Wang J, Li S, Zhou W, Xu W. Predictive value of (18)F-FDG PET\/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner\/center study with external validation. Eur J Nucl Med Mol Imaging. 2023;50:1869\u201380. https:\/\/doi.org\/10.1007\/s00259-023-06150-2.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07306-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07306-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07306-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:42Z","timestamp":1759394202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07306-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7306"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07306-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center prospective clinical trial was performed at Peking University First Hospital, and the study was approved by the institutional ethics committee (2022SR053-001), waiving the need for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent prior to imaging.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}